Patient demographics, selected laboratory values, clinical history, and immunotherapy drugs included in this study

Age
 Median53.5
 Range18–84
Sex
 Female29
 Male21
No. of metastatic sites
  < 337
  > =313
LDH
  < =ULN36
  > ULN14
ECOG PS
 0–148
 22
Albumin
  > =3.5 g/dl46
  < 3.5 g/dl4
RMH score
  < 243
  > =27
Prior treatments
 Median3
 Range0–12
 Anthracycline30
 Ifosfamide14
 Gemcitabine22
 Docetaxel13
 Platinum8
Investigational therapies
 anti-CCR4 and anti-PD-L14
 anti-PD-17
 anti-PD-L17
 anti-TIM-31
 anti-CTLA-45
 anti-CTLA-4 and immunomodulator7
 anti-CTLA-4 and KIT inhibitor10
 Dendritic cell vaccine7
 Interleukin-21
 anti-TGF-β1